Serum Chemokine and Cytokine Levels As Indicators of Disease Activity in Patients with Systemic Sclerosis

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2010 Nov 5

PMID 21049277

Citations 38

Authors

Minoru Hasegawa

Manabu Fujimoto

Takashi Matsushita

Yasuhito Hamaguchi

Kazuhiko Takehara

Shinichi Sato

Affiliations

Soon will be listed here.

Abstract

To determine the clinical utility of serum levels of chemokines and cytokines for the evaluation of disease activity in patients with systemic sclerosis (SSc), concentrations of four chemokines (interferon γ-inducible protein-10 [IP-10, CXCL10], monokine induced by interferon γ [MIG/CXCL9], monocyte chemoattractant protein-1 [MCP-1/CCL2], interleukin 8 [IL-8/CXCL8]) and six cytokines (IL-2, IL-4, IL-6, IL-10, tumor necrosis factor [TNF]-α, interferon [IFN]- γ) were measured using cytometric beads array kits in serum samples from 31 Japanese patients with SSc and 20 normal controls. Clinical and laboratory data and serum chemokine and cytokine levels were assessed for each patient at their first visit and each subsequent year for 3 years. Among these chemokines and cytokines, serum levels of IP-10, MIG and MCP-1 were significantly elevated in SSc patients compared with normal controls at their first visit. Serum MCP-1 levels declined year and year, along with improvement for skin sclerosis. The variations of MCP-1, but not IP-10 and MIG, were significantly associated with the variations of skin thickness score and vital capacity during 3 years. These results suggest that MCP-1 is a serological indicator of the activity of skin and lung involvement in patients with SSc. However, a longer-term prospective study in a larger population will be needed to confirm its clinical utility as predictors of outcomes.

Citing Articles

Immune mechanisms in fibrotic interstitial lung disease.

Kamiya M, Carter H, Espindola M, Doyle T, Lee J, Merriam L Cell. 2024; 187(14):3506-3530.

PMID: 38996486 PMC: 11246539. DOI: 10.1016/j.cell.2024.05.015.

Association of serum Ly6/PLAUR domain-containing protein 1 levels with skin sclerosis in systemic sclerosis.

Sugimori A, Omori I, Iwasawa O, Saito H, Nakajima H, Matsuno A Sci Rep. 2024; 14(1):5572.

PMID: 38448661 PMC: 10918060. DOI: 10.1038/s41598-024-56221-z.

Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.

Ghuman A, Khanna D, Lin C, Furst D, Raghu G, Martinez F Rheumatology (Oxford). 2023; 63(2):472-481.

PMID: 37228011 PMC: 10836965. DOI: 10.1093/rheumatology/kead234.

Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease.

Pugashetti J, Khanna D, Kazerooni E, Oldham J Immunol Allergy Clin North Am. 2023; 43(2):411-433.

PMID: 37055096 PMC: 10584384. DOI: 10.1016/j.iac.2023.01.012.

Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease.

Makol A, Nagaraja V, Amadi C, Pugashetti J, Caoili E, Khanna D Expert Rev Clin Immunol. 2023; 19(6):613-626.

PMID: 36999788 PMC: 10698514. DOI: 10.1080/1744666X.2023.2198212.

References

Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos J . Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum. 2001; 44(6):1382-6. DOI: 10.1002/1529-0131(200106)44:6<1382::AID-ART231>3.0.CO;2-T. View

Yamamoto T, Eckes B, Krieg T . High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol. 2001; 31(10):2936-41. DOI: 10.1002/1521-4141(2001010)31:10<2936::aid-immu2936>3.0.co;2-0. View

LeRoy E, Black C, FLEISCHMAJER R, Jablonska S, Krieg T, Medsger Jr T . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2):202-5. View

Steen V, Medsger Jr T, Osial Jr T, Ziegler G, Shapiro A, Rodnan G . Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med. 1984; 76(5):779-86. DOI: 10.1016/0002-9343(84)90986-0. View

Steen V, Powell D, Medsger Jr T . Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988; 31(2):196-203. DOI: 10.1002/art.1780310207. View

Sato S, Ihn H, Kikuchi K, Takehara K . Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum. 1994; 37(3):391-4. DOI: 10.1002/art.1780370313. View

Hasegawa M, Sato S, Takehara K . Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary.... Clin Exp Immunol. 1999; 117(1):159-65. PMC: 1905464. DOI: 10.1046/j.1365-2249.1999.00929.x. View

Liao F, Rabin R, Yannelli J, Koniaris L, Vanguri P, Farber J . Human Mig chemokine: biochemical and functional characterization. J Exp Med. 1995; 182(5):1301-14. PMC: 2192190. DOI: 10.1084/jem.182.5.1301. View

Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K . The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol. 2008; 158(3):487-95. PMC: 2344460. DOI: 10.1111/j.1365-2133.2007.08392.x. View

10.

Steen V, Medsger Jr T . Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000; 43(11):2437-44. DOI: 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U. View

11.

Gharaee-Kermani M, Denholm E, Phan S . Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem. 1996; 271(30):17779-84. DOI: 10.1074/jbc.271.30.17779. View

12.

Atamas S, White B . The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol. 2003; 15(6):772-7. DOI: 10.1097/00002281-200311000-00015. View

13.

. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5):581-90. DOI: 10.1002/art.1780230510. View

14.

Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S . Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci. 2004; 35(1):43-51. DOI: 10.1016/j.jdermsci.2004.03.001. View

15.

Roumm A, Whiteside T, Medsger Jr T, Rodnan G . Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984; 27(6):645-53. DOI: 10.1002/art.1780270607. View

16.

Luster A, Unkeless J, Ravetch J . Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature. 1985; 315(6021):672-6. DOI: 10.1038/315672a0. View

17.

Clements P, Lachenbruch P, Seibold J, Zee B, Steen V, Brennan P . Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993; 20(11):1892-6. View

18.

Varga J, Abraham D . Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007; 117(3):557-67. PMC: 1804347. DOI: 10.1172/JCI31139. View

19.

Whitfield M, Finlay D, Murray J, Troyanskaya O, Chi J, Pergamenschikov A . Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A. 2003; 100(21):12319-24. PMC: 218756. DOI: 10.1073/pnas.1635114100. View

20.

Denton C, Black C . Targeted therapy comes of age in scleroderma. Trends Immunol. 2005; 26(11):596-602. DOI: 10.1016/j.it.2005.09.002. View